Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
Fiction
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/49/1e/7e/491e7ef8-6996-a544-5e98-e0cc06aa0149/mza_10921017996814677989.png/600x600bb.jpg
touchPODCAST
touchpodcast
517 episodes
1 week ago
Show more...
Science
RSS
All content for touchPODCAST is the property of touchpodcast and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Show more...
Science
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/49/1e/7e/491e7ef8-6996-a544-5e98-e0cc06aa0149/mza_10921017996814677989.png/600x600bb.jpg
Focus on treatment advances for ATTRv: A heterogeneous, highly debilitating and ultimately fatal disease
touchPODCAST
19 minutes 6 seconds
3 months ago
Focus on treatment advances for ATTRv: A heterogeneous, highly debilitating and ultimately fatal disease
touchEXPERT FOCUS for touchNEUROLOGY and touchCARDIO Listen to Dr Chafic Karam share expert insights on diagnosing and managing ATTRv amyloidosis. In this short interview, he covers red-flag symptoms, diagnostic challenges and key strategies for differentiating ATTRv. He also discusses current treatment options, including TTR stabilisers and gene silencers, as well as emerging therapies aimed at improving patient outcomes. The expert: Dr Chafic Karam, University of Pennsylvania, Philadelphia, PA, USA This touchPODCAST is for HCPs in the USA only. This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our websites:  https://touchneurology.com/ and https://touchcardio.com/
touchPODCAST